PTPRF

Across TCGA pan-cancer cohorts, PTPRF mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PTPRF data layer compared with 23 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PTPRF mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PTPRF expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, GBM, and HNSC are the cancer types where PTPRF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.699	1.000	.003	14	view →
GBM	DFS	Tertile	All	0.198	0.483	.013	8	view →
HNSC	OS	Tertile	All	0.439	1.000	.040	8	view →
LUAD	DFS	Tertile	All	0.486	0.767	.019	6	view →
LSCC	DFS	Median	All	0.826	0.636	.040	3	view →
PDAC	DFS	Quartile	III,IV	0.354	0.812	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PTPRF–CCRCC (OS)

Open the CCRCC breakdown →